🔗 Share this article

While the United States proceeds with unprecedented revisions to its immunization guidelines, an unexpected name appears unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by expressing skepticism about COVID-19 shots during the pandemic and has zeroed in on potential fatalities following Covid immunization in her short tenure at the FDA.

Proposed Changes to Childhood Vaccine Schedule

Health officials planned to unveil radical revisions to the childhood vaccine schedule earlier this month, aligning the US with the Danish national calendar, sources say – a major change that would place the US at odds with a large portion of the world with little proof for public health gain. This reveal has been delayed until the coming year.

Instead of the director of the vaccine center, Høeg is scheduled to present at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to lead the division this year.

A Shift at the Regulatory Body

This interim role may indicate a tighter collaboration between the drug and biologics branches as Dr. Høeg and Prasad solidify control at the FDA – and it signals a greater focus upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting certain pediatric shot schedules in the US in order to be more like the Danish model, a society with comprehensive healthcare and a number of inhabitants roughly the size of the state of Wisconsin.

To date public appearances, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, chief of the FDA’s CBER – rather than medication approval.

Concerns Over Qualifications

Høeg has no apparent experience in medication creation, approval processes or management, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and CBER since March.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a major agency. She has no expertise in drug approvals.”

Previous commissioners of the center would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that previous people who led the center have had.”

The drug center has an vast range of responsibilities at the agency, she emphasized.

“The public just focuses on the new drug program, but the generic drug division clears thousands of generic medications. There’s a biosimilars program, non-prescription drug unit and so forth, and all of those must be managed,” she noted. “The responsibility you overlook, that is the part that I always told people is going to bite you.”

Additionally, a substantial administrative element to the role, which supervises over 5,000 staff members. “It is a huge administrative position, if you perform it correctly,” Woodcock added.

Official Statement and Disputed Programs

In response to questions about Dr. Høeg's fitness for the role and whether this appointment represents increased cooperation among agency officials on vaccines, a spokesperson said that the “inquiries are based on incorrect assumptions”.

“This background matches the responsibilities of her role,” the spokesperson explained, noting the period Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a contentious rapid drug-approval program that apparently worried her preceding directors. “By what process are these drugs being chosen for this fast-track system? Who is making the choices?” Howard said. “There is a lot of secrecy occurring at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration appears to be shifting towards more relaxed oversight of most medications, with the exception of vaccines.”

Documented Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if concerning, track record, Howard said. She released a analysis using unconfirmed volunteer-provided data to estimate the rate of heart inflammation after Covid immunization. She counseled the Florida surgeon general Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the current federal leadership featured changing guidelines for novel immunizations and ending “optional” immunizations, she stated after the election on a podcast. At the FDA, Dr. Høeg has allegedly suggested barring teenage boys from getting Covid vaccinations.

“She’s an complete true believer who commences with her preconceived notions and tailors the evidence to accommodate the data in a highly deceptive, dishonest way,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg aligned with other contrarians, {like|